MedTrace Logo

Bisantrene for Relapsed /Refractory AML

NCT03820908 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-08-07

No results posted yet for this study

Summary

Induction of response in patients with AML that are either primary resistant (failed induction and or salvage therapy) or relapsed including post allogeneic stem cell transplantation and failed salvage therapy or cannot receive additional anthracycline .

Conditions

  • Acute Myelogenous Leukemia
  • Allogeneic Stem Cell Transplantation

Interventions

DRUG

Bisantrene

The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.

Sponsors & Collaborators

  • Race Oncology Ltd

    collaborator INDUSTRY

  • Sheba Medical Center

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-18
Primary Completion
2020-05-19
Completion
2020-07-22

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03820908 on ClinicalTrials.gov